Catalog No.
DHB94501
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
LeIF D, Interferon alpha-1/13, IFNA1, Interferon alpha-D, IFN-alpha-1/13
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01562
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MDX-1103, MEDI-545, CAS: 1006877-41-3
Clone ID
Sifalimumab
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients, PMID: 23434567
Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis, PMID: 28673504
An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus, PMID: 34244988
Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations, PMID: 32237942
Biologic therapy for autoimmune diseases: an update, PMID: 23557513
Biologic therapy in the idiopathic inflammatory myopathies, PMID: 31680207
Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus, PMID: 31565077
Biologics for idiopathic inflammatory myopathies, PMID: 28817464
Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials, PMID: 32960720
Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature, PMID: 21994039
Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation, PMID: 29869293
Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus, PMID: 27270345
Efficacy of sifalimumab for treatment of skin injury caused by systemic lupus erythematosus, PMID: 31651869
From mechanism to therapies in systemic lupus erythematosus, PMID: 28118202
Impaired health status and the effect of pain and fatigue on functioning in clinical trial patients with systemic lupus erythematosus, PMID: 24085548
Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment, PMID: 24939511
Interferon targeted therapies in systemic lupus erythematosus, PMID: 32185249
Interferon α-targeted therapy, PMID: 23994795
Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?, PMID: 27497254
Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics, PMID: 26767526
Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients, PMID: 26659791
Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus, PMID: 23754736
S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases, PMID: 33748735
Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study, PMID: 30791804
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study, PMID: 21798883
Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies, PMID: 26270565
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study, PMID: 23400715
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study, PMID: 27009916
Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab, PMID: 25925951
Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis, PMID: 24357810
Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE, PMID: 29460699
Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System, PMID: 26099519
Targeted therapies in systemic lupus erythematosus, PMID: 23963429
Targeting interferons in systemic lupus erythematosus: current and future prospects, PMID: 25940912
Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus, PMID: 28000522
Type I interferon blockade in systemic lupus erythematosus: where do we stand?, PMID: 24344319
Update on clinical trials in systemic lupus erythematosus, PMID: 27314466
Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus, PMID: 20392292
Why, why, why de-lupus (does so badly in clinical trials), PMID: 26786849
For research use only. Not for human or drug use.
